PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

Conditions:   Advanced Malignant Solid Neoplasm;   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Metastatic Malignant Solid Neoplasm;   Progesterone Receptor Negative;   PTEN Gene Mutation;   Triple-Negative Breast Carcinoma;   Unresectable Solid N eoplasm Interventions:   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: PI3Kbeta Inhibitor AZD8186 Sponsor:   National Cancer Institute (NCI) Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2uJOvE2
via IFTTT